Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin

Vox Sanguinis

Volumn 76, Issue 3, 1999, Pages 181-186

  Murozuka, T ^a   Aoki, M ^a   Kimura, N ^a   Sotoyama, K ^a   Abe, I ^a   Izumi, H ^a   Emura, H ^a   Takeda, Y ^a   Nanakawa, H ^a   Katsubayashi, Y ^a   Takeuchi, T ^a   Ito, H ^a   Hirakawa, S ^b   Mitsunaga, S ^b   Tadokoro, K ^b   Kanemitsu, K ^c   Miyamoto, M ^c   Yamanaka, R ^c   Nishioka, K ^c  

^a Japanese Red Cross Society   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c SUWA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DETERGENT; HEPATITIS B SURFACE ANTIGEN; HUMAN SERUM ALBUMIN; MONOCLONAL ANTIBODY; SOLVENT; VIRUS DNA;

ARTICLE; BLOOD TRANSFUSION; CONTAMINATION; ERROR; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; KINETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RED CROSS; SAFETY; TIME; VIRUS INACTIVATION; VIRUS TRANSMISSION;

FACTOR VIII; HEALTH CARE SECTOR; HEPATITIS B VIRUS; HUMANS; PLASMA; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 0032915498     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000031046     Document Type: Article

References (18)

1. Japanese Red Cross non-A non-B hepatitis Research Group: Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991;338:1040-1041.
2. Watanabe J, Matsumoto C, Fujimuva K, Shimada T, Yosizawa H, Okamoto H, Iizuka H, Tango T, Ikeda H, Endo N, Mazda T, Nojiri T, Aoyama K, Kanemitsu K, Yamano H, Mizui M, Yokoishi F, Tokunaga K, Nishioka K: Predictive value of screening tests for persistent hepatitis C virus infection evidence by viraemia: Japanese experience. Vox Sang 1993; 65:199-203.
3. Nishioka K: Transfusion-transmitted HBV and HCV. Vox Sang 1996;70(suppl 3):4-8.
4. Sato H, Okochi K: Transfusion transmitted infection of HTLV-I and its prevention. Gann Monogr Cancer Res 1992;39:151-162.
5. Conn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-475.
6. Horowitz B, Wiebe ME, Lippin A, Stryker MH: Inactivation of viruses in labile blood derivatives. 1. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985;25:516-522.
7. Iizuka H, Ohmura K, Ishijima A, Satoh K, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M: Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang 1992;63:107-111.
8. Holland PM, Abramson RD, Watson R, Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5′3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991;88:7276-7280.
9. Schroeder DD, Mozen MM: Australia antigen: Distribution during Cohn cold ethanol.
10. Berg R, Björing H, Berntsen K, Epsmark Å: Recovery of Australian antigen from fractionation of human plasma. Science 1970;168: 1462-1464.
11. Trepo C, Hantz O, Jacquier MF, Nemoz G, Cappel R, Trepo D: Different fates of hepatitis B virus markers during plasma fractionation. Vox Sang 1978;35:143-148.
12. Gellis SS, Neefe JR, Stokes J Jr: Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 1948;27:239-244.
13. McClelland DBL: Safety of human albumin as a constituent of biologic therapeutic products. Transfusion 1998;38:690-697.
14. Hilfenhaus J, Groner A, Nowak T, Weimer T: Analysis of human plasma products: Polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion 1997;37:935-940.
15. Griffith MJ: Biochemical characterization of the method M AHF process developed to reduce the risk of virus transmission; in Roberts HR (ed): Proceedings of the Symposium on Biotechnology and the Promise of Pure F. Monte-Carlo, Baxter 1988, pp 69-85.
16. Prince AM, Horowitz B, Brotman B: Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1986;i:706-710.
17. Horowitz B, Price AM, Horowitz MS, Watklevicz C: Viral safety of solvent/detergent treated blood products; in Rivat C, Stolz JF (eds): Biotechnology of blood proteins. Colloque INSERM 1993;227:237-247.
18. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.